Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients

Thrombosis and Haemostasis

Volumn 102, Issue 1, 2009, Pages 49-55

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Blood coagulation; End stage renal disease (ESRD); Hypercoagulability; Kynurenines; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ANTHRANILIC ACID; FIBRINOGEN; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRYPTOPHAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCOAGULABILITY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UREMIA;

ADULT; AGED; BLOOD COAGULATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KYNURENINE; LIPOPROTEINS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROTEIN PRECURSORS; PROTHROMBIN; RENAL DIALYSIS; THROMBOPHILIA; THROMBOPLASTIN; UREMIA;

EID: 67749116092     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0696     Document Type: Article

References (36)

1. Prichard S. Cardiovascular risk in peritoneal dialysis. Contrib Nephrol 2003; 140: 82-90.
2. Lameire N, Bernaert P, Lambert M-C, et al. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46 (Suppl 48): S31-S38.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3): S112-S119.
4. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (Suppl 1): S117-S131.
5. Viener A, Aviram M, Better OS, et al. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 1986; 43: 139-143.
6. Toulon P, Jacquot C, Capron L, et al. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing hemodialysis. Thromb Haemost 1987; 57: 263-268.
7. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int 2001; 21: 158-165.
8. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76: 56-61.
9. Vaziri ND, Shah GM, Winer RL, et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53: 173-180.
10. Wiiger MT, Prydz H. The changing faces of tissue factor biology - a personal tribute to the understanding of the "extrinsic coagulation activation". Thromb Haemost 2007; 98: 38-42.
11. Engelmann B, Luther T, Müller I. Intravascular tissue factor pathway - a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8.
12. Farred J, Hoppensteadt DA, Leya F, et al. Thrombogenesis in myocardial infartion and related syndromes: the role of molecular markers in diagnosis and management. Clin Appl Thromb/Haemost 1999; 5: 78-91.
13. Kaikita K, Takeya M, Ogawa H, et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-188.
14. Pawlak K, Borawski J, Naumnik B, et al. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res 2003; 109: 247-251.
15. Pawlak K, Naumnik B, Brzosko S, et al. Oxidative stress- a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol 2004; 24: 154-161.
16. Pawlak K, Pawlak D, Mysliwiec M. Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagul Fibrinolysis 2007; 18: 467-471.
17. Zemanova P, Opatrny K Jr, Opatrna S, et al. Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis. Kidney Blood Press Res 2003; 26: 368-375.
18. Sagripanti A, Cozza V, Baicchi U, et al. Increased thrombin generation in patients with chronic renal failure. Int J Clin Lab Res 1997; 27: 72-75.
19. Kario M, Matsuo T, Yamada T, et al. Factor VII hyperactivity in chronic dialysis patients. Thromb Res 1992; 67: 105-109.
20. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309-379.
21. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004; 4: 12-17.
22. Pawlak D, Tankiewicz A, Matys T, et al. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol 2003; 54: 175-189.
23. Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 2001; 52: 755-766.
24. Pawlak D, Pawlak K, Malyszko J, et al. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol 2001; 33: 399-404.
25. Pawlak K, Domaniewski T, Mysliwiec M, et al. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204: 309-314.
26. Pawlak K, Brzosko S, Mysliwiec M, et al. Kynurenine, quinolinic acid - the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 2009; 204: 561-566.
27. Schroecksnadel K, Frick B, Winkler C, et al. Crucial role of interferon-γ and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006; 4: 205-213.
28. Baldo-Enzi G, Baiocchi MR, Bertazzo A, et al. Tryptophan and atherosclerosis. Adv Exp Med Biol 1996; 398: 429-432.
29. Rudzite V, Sileniece G, Liepina D, et al. Impairment of kynurenine metabolism in cardiovascular disease. Adv Exp Med Biol 1991; 294: 663-667.
30. Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33: 550-554.
31. Koenig W, Ernst E. Fibrinogen and atherothrombogenesis. Curr Opin Lipidol 1993; 4: 471-476.
32. Irish A. Cardiovascular disease, fibrinogen and the acute phase response. Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 133-139.
33. Brisseau GF, Dackiw APB, Cheung PYC, et al. Posttranscriptional regulation of macrophage tissue factor expression by antioxidants. Blood 1995; 85: 1025-1035.
34. Halliwell B. The role of oxygen radicals in human disease, with particular reference to vascular system. Haemostasis 1993; 23 (Suppl 1): 118-126.
35. Saigo M, Waters DD, Abe S, et al. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, protein C and S, tissue factor, D-dimer, and prothrombin fragment 1+2 in men with acute myocardial infarction ≤45 years of age. Am J Cardiol 2004; 94: 1410-1413.
36. Molino D, De Santo MG, Marotta R, et al. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antithrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol 2004; 24: 495-501.